BioCina, a contract development and manufacturing organization (CDMO) has appointed Mark Womack CEO. Womack will be responsible for the continued growth, commercial strategy and organizational culture of BioCina.

Womack’s announcement follows the appointment of founding CEO, Ian Wisenberg, to executive chairman of BioCina Board of Directors.

“Over the past two years, our team and investment expanded BioCina from a single product commercial facility into Australia’s highest quality biologics CDMO,” said Wisenberg. “This foundational success has created a natural point for the company to transition leadership to support BioCina’s future commercial growth. We are very fortunate to have someone with Mark’s vision and pedigree of growing high value CDMOs to lead our company into its next phase. I am excited for this new chapter and for Mark to take the reins as CEO at BioCina.”

“I’m tremendously excited to lead the highly talented and deeply committed BioCina team, and to build on all of the success they’ve achieved to-date,” said Womack. Leveraging BioCina’s core strengths, we will become a preeminent Global Biologics CDMO through industry-leading quality, a client-centric approach and on-time delivery of client programs.”

Womack brings to BioCina 30 years of experience across executive leadership, management consulting and CDMO commercial operations.

According to the company, he has a proven record of success in delivering exceptional growth and profit in every role. Most recently, Womack served as CEO of KBI Biopharma and Selexis SA, achieving a run rate of over 30% year on year revenue increase in only six months and implementing a new commercial strategy that generated significantly greater deal size and profitability.

Prior, Womack served as the CEO and Managing Director of Stelis Biopharma, where he spearheaded the development and implementation of the infrastructure for a pure-play CDMO, including an end-to-end biologics offering across multiple facilities.
In 2021, he oversaw the company’s efforts to build and qualify a state-of-the-art vaccine facility capable of clinical and commercial-scale manufacturing in record time. 

Womack also served as the chief business officer at AGC Biologics. His extensive experience driving organizational performance improvements garnered nearly 300% sales increase in just two years.